Ping An Biomedical Sets 1-for-40 Reverse Split Effective October 23

summarizeSummary

Ping An Biomedical will execute a 1-for-40 reverse split on October 23, 2026, cutting shares outstanding from ~125.1 million to ~3.13 million and resetting the price to roughly $4.88 — a move aimed at restoring Nasdaq bid compliance after the delisting risk flagged in its September half-year report.

check_boxKey Events · Corporate Governance and Compliance · PASW

• 1-for-40 Reverse Split Approved

  Board unanimously set a 40-for-1 consolidation of class A and class B shares effective October 23, 2026, under authority granted at the March 18, 2026 EGM.

• Share Count Cut to ~3.13 Million

  112,867,000 class A and 12,250,000 class B shares become approximately 2,821,675 class A and 306,250 class B shares, subject to rounding up of fractional entitlements.

• Price and Par Value Reset

  At today's $0.122, the split implies a theoretical ~$4.88 per share; par value rises from $0.0000625 to $0.0025 and the new CUSIP is G5880S139.

• Delisting Risk Is the Backdrop

  The September 11, 2026 half-year report disclosed Nasdaq delisting risk; the split is the standard remedy to regain the $1.00 minimum bid, though compliance is not guaranteed.

auto_awesomeAnalysis · PASW · Manufacturing

The 40-for-1 consolidation takes PASW from about 125.1 million shares to roughly 3.13 million, lifting the theoretical price from $0.122 to about $4.88 and giving the company a path to regain Nasdaq's $1.00 minimum bid. That matters because the timeline shows a delisting risk already disclosed in the September 11 half-year report, and a reverse split is the standard remedy. The catch: the split changes nothing about the business, and the company itself flags that Cayman counsel says the consolidation and amended articles may still need shareholder ratification at a general meeting — an unresolved procedural step. Watch the October 23 open for split-adjusted trading and whether the bid holds above $1.00.